ABSTRACT
The 17th Workshop on Recent Issues in Bioanalysis (17th WRIB) took place in Orlando, FL, USA on 19-23 June 2023. Over 1000 professionals representing pharma/biotech companies, CROs, and multiple regulatory agencies convened to actively discuss the most current topics of interest in bioanalysis. The 17th WRIB included 3 Main Workshops and 7 Specialized Workshops that together spanned 1 week to allow an exhaustive and thorough coverage of all major issues in bioanalysis of biomarkers, immunogenicity, gene therapy, cell therapy and vaccines.Moreover, in-depth workshops on "EU IVDR 2017/746 Implementation and impact for the Global Biomarker Community: How to Comply with these NEW Regulations" and on "US FDA/OSIS Remote Regulatory Assessments (RRAs)" were the special features of the 17th edition.As in previous years, WRIB continued to gather a wide diversity of international, industry opinion leaders and regulatory authority experts working on both small and large molecules as well as gene, cell therapies and vaccines to facilitate sharing and discussions focused on improving quality, increasing regulatory compliance, and achieving scientific excellence on bioanalytical issues.This 2023 White Paper encompasses recommendations emerging from the extensive discussions held during the workshop and is aimed to provide the bioanalytical community with key information and practical solutions on topics and issues addressed, in an effort to enable advances in scientific excellence, improved quality and better regulatory compliance. Due to its length, the 2023 edition of this comprehensive White Paper has been divided into three parts for editorial reasons.This publication (Part 2) covers the recommendations on Biomarkers, IVD/CDx, LBA and Cell-Based Assays. Part 1A (Mass Spectrometry Assays and Regulated Bioanalysis/BMV), P1B (Regulatory Inputs) and Part 3 (Gene Therapy, Cell therapy, Vaccines and Biotherapeutics Immunogenicity) are published in volume 16 of Bioanalysis, issues 9 and 7 (2024), respectively.
Subject(s)
Biomarkers , Cell- and Tissue-Based Therapy , Vaccines , Humans , Biomarkers/analysis , Vaccines/immunology , Flow Cytometry , Biological Assay/methods , European Union , WhiteABSTRACT
Malocclusion is a common problem in dogs. Linguoverted canine teeth (class I malocclusion) can cause palatal defects, oronasal fistulae, dental wear, and periodontal disease. Mandibular distoclusion (class II malocclusion), in which the mandibular arch occludes caudal to its normal position relative to the maxillary arch, can further contribute to lingual displacement of mandibular canine teeth. Traditionally, a flowable self-curing bisacrylic composite material has been used. The method described here uses a light cure acrylic denture base material utilizing multiple customized segments to construct the appliance to the desired shape and size necessary to achieve a functional incline plane.
Subject(s)
Dog Diseases , Malocclusion, Angle Class II , Malocclusion , Animals , Cephalometry/veterinary , Cuspid , Dog Diseases/therapy , Dogs , Light , Malocclusion/veterinary , Malocclusion, Angle Class II/veterinary , MaxillaABSTRACT
An 18-month-old neutered male labradoodle was treated with surgical debridement for maxillary osteomyelitis and sequestrum formation. Histopathologic findings of the necrotic bone were consistent with Cryptococcus subspecies, confirmed with latex agglutination serum titer testing. The patient responded to a combination of fluconazole and surgical debridement and was titer negative after 8 months of medical therapy. The patient never exhibited signs of systemic illness which is commonly reported with cryptococcosis. Cryptococcus subspecies infection in dogs in the Pacific Northwest is part of an ongoing outbreak in the region, first reported in 2001, and is associated with specific risk factors. This is the first published case of oral cryptococcosis from primary inoculation.
Subject(s)
Cryptococcosis/veterinary , Dog Diseases/diagnosis , Maxillary Diseases/veterinary , Osteomyelitis/veterinary , Osteonecrosis/veterinary , Animals , Antifungal Agents/administration & dosage , Cryptococcosis/diagnosis , Cryptococcosis/drug therapy , Cryptococcosis/surgery , Cryptococcus/physiology , Debridement/veterinary , Dog Diseases/drug therapy , Dog Diseases/surgery , Dogs , Fluconazole/administration & dosage , Male , Maxillary Diseases/diagnosis , Maxillary Diseases/drug therapy , Maxillary Diseases/surgery , Osteomyelitis/diagnosis , Osteomyelitis/drug therapy , Osteomyelitis/surgery , Osteonecrosis/diagnosis , Osteonecrosis/drug therapy , Osteonecrosis/surgeryABSTRACT
OBJECTIVES: We investigated the signaling pathways activated in response to interleukin 6 (IL-6) in pancreatic cell lines, with a focus on signal transducer and activator of transcription 3 (STAT3) and proto-oncogene serine/threonine-protein (Pim-1) kinase. METHODS: Interleukin 6 receptor (IL-6R) expression and IL-6-induced cell signaling was measured by Western blotting in human pancreatic cell lines. Cucurbitacin I was used as a pharmacological tool to investigate the role of STAT3 in Pim-1 activation. Stably overexpressing Pim-1 kinase cell lines were characterized for their response to IL-6 in vitro and for their growth rate as flank tumors in scid mice. RESULTS: Interleukin 6 receptor was expressed across multiple cancer cell lines. In Panc-1 cells, IL-6 treatment increased expression of phosphorylation of signal transducer and activator of transcription 3 and Pim-1 kinase. Cucurbitacin I treatment alone increased pErk1/2 expression in wild-type and Pim-1-overexpressing cell lines and resulted in exaggerated Pim-1 kinase protein levels in control and IL-6-stimulated cells, suggesting that up-regulation of Pim-1 may be partially STAT3 independent. Pim-1 overexpression did not significantly affect growth rate in vitro or in vivo in Panc-1 or MiaPaCa2 cell lines. CONCLUSIONS: Interleukin 6 activates STAT3 and stimulates Pim-1 kinase in pancreatic cell line models. The regulation and consequence of Pim-1 expression seems to be highly context dependent.
Subject(s)
Interleukin-6/pharmacology , Pancreatic Neoplasms/genetics , Proto-Oncogene Proteins c-pim-1/genetics , STAT3 Transcription Factor/genetics , Animals , Apoptosis/drug effects , Blotting, Western , Cell Line, Tumor , Cell Proliferation/drug effects , Gene Expression Regulation, Neoplastic/drug effects , Humans , Male , Mice , Mice, SCID , Mitogen-Activated Protein Kinase 1/genetics , Mitogen-Activated Protein Kinase 1/metabolism , Mitogen-Activated Protein Kinase 3/genetics , Mitogen-Activated Protein Kinase 3/metabolism , Pancreatic Neoplasms/metabolism , Pancreatic Neoplasms/pathology , Proto-Oncogene Mas , Proto-Oncogene Proteins c-pim-1/metabolism , Receptors, Interleukin-6/genetics , Receptors, Interleukin-6/metabolism , Reverse Transcriptase Polymerase Chain Reaction , STAT3 Transcription Factor/metabolism , Transplantation, Heterologous , Triterpenes/pharmacology , Tumor Burden/geneticsABSTRACT
Selective blockade of hypoxia-inducible gene expression by designed small molecules would prove valuable in suppressing tumor angiogenesis, metastasis and altered energy metabolism. We report the design, synthesis, and biological evaluation of a dimeric epidithiodiketopiperazine (ETP) small molecule transcriptional antagonist targeting the interaction of the p300/CBP coactivator with the transcription factor HIF-1alpha. Our results indicate that disrupting this interaction results in rapid downregulation of hypoxia-inducible genes critical for cancer progression. The observed effects are compound-specific and dose-dependent. Controlling gene expression with designed small molecules targeting the transcription factor-coactivator interface may represent a new approach for arresting tumor growth.
